Adoptive immunotherapy for the treatment of patients with hepatocellular carcinoma

Abstract

Adoptive immunotherapy was performed administrating autologous lymphokine-activated killer cell via hepatic artery for 7 cases with primary hepatocellular carcinoma. Both of the natural killer activity and the lymphokine-activated killer activity in the peripheral blood lymphocyte were significantly increased after the treatment. A reduction of the tumor size was recognized in 2 cases out of the 7 cases after the treatment and, also a decrease in the serum alpha-feto protein level was found in all cases who showed higher level before the treatment.